Argenx Shares Are Trading Higher. Multiple Firms Raised Their Respective Price Targets on the Stock.

BenzingaNov 2 02:41

Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'

BenzingaNov 2 00:28

Argenx Downgraded at Baird as Shares Get Pricey

Seeking AlphaNov 1 23:20 · Ratings

This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

BenzingaNov 1 23:12

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195

BenzingaNov 1 20:21 · Ratings

Baird Downgrades Argenx to Neutral, Raises Price Target to $650

BenzingaNov 1 18:43 · Ratings